Activation of these different pathways is mediated by a number of membrane receptors, which subsequently activate various signaling pathways leading to NF-κB activation, such as Toll-like receptor (TLR), tumor necrosis factor receptor (TNFR), interleukin-1 receptor (IL-1R), T cell receptor (TCR), B cell receptor (BCR), etc. In a series of studies, small-molecule inhibitors of the NF-κB signaling pathway have been shown to have significant therapeutic potential in inflammatory diseases and cancers, with implications for future research. Here, NFKB1 is linked to cancer.